Concurrently, this demonstrates that APLNs used in treating IMQ-induced mouse psoriasis can mitigate skin psoriasis in mice through the diminished levels of cytokines associated with psoriasis, including IL-17F, IL-22, and IL-17A etc. The gene discussed is IL22; the disease is psoriasis.